Development of a Ga-68 labeled triptorelin analog for GnRH receptor imaging

Radiochimica Acta

Volumn 104, Issue 4, 2016, Pages 247-255

  Zoghi, Masoumeh ^a   Niazi, Ali ^a   Jalilian, Amir R ^b   Johari Daha, Fariba ^b   Alirezapour, Behrouz ^b   Ramezanpour, Sorour ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b Nuclear Science and Technology Research Institute (NSTRI)   (Iran)

^c K N TOOSI UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

68Ga; block test; DOTA; GnRH; peptide synthesis; quality control; triptorelin hydrazide

Indexed keywords

EID: 84962705656     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1515/ract-2015-2443     Document Type: Article

References (25)

1. Reshkin S.J., Pezzetta A., Albarani V., Schittulli F., Paradiso A.: Characterization of a 3H-GnRH method for the measurement of GnRH binding sites in human breast cancer and breast cancer cell lines. Int. J. Oncol. 7, 371-375 (1995).
2. FeketeM., Wittliff J.L., Schally A.V.: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J. Clin. Lab. Anal. 3, 137-147 (1989).
3. Paradiso A., Pezzetta A., Cellamare G., Schittulli F., Marzullo F., Reshkin S.J.: GnRH receptors in human breast cancer and its contiguous not-involved breast tissue. J. Endocrinol. Invest. 23, 90-96 (2000).
4. Srkalovic G., Wittliff J.L., Schally A.V.: Detection and partial characterization of receptors for (D-Trp6)-luteinizing-hormone releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res. 50, 1841-1846 (1990).
5. Emons G., Pahwa G.S., Brack G., Sturm R., Oberheuser F., Knupperi R.: Gonadotrophin-releasing-hormone binding sites in human epithelial ovarian carcinoma. Eur. J. Cancer. Clin. Oncol. 25, 215-221 (1989).
6. FeketeM., Zalatmai A., Comaru-Schally A.M., Schally A.V.: Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4, 521-528 (1989).
7. Eidne K.A., Flanagan C.A., Harris N.S., Millar R.P.: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J. Clin. Endocrinol. Metab. 64, 425-432 (1987).
8. Miller W.R., Scott W.N., Morris R., Fraser H.M., Sharpe R.M.: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313, 231-233 (1985).
9. Flanagan C.A., Fromme B.J., Davidson J.S., Millar R.P.: A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. Endocrinology 139, 4115-4119 (1998).
10. Grzegorzewski W.J., Skipor J., Wasowska B., Krzymowski T.: Countercurrent transfer of 125I-LHRH in the perihypophyseal cavernous sinus-carotid retevascular complex, demonstrated on isolated pig heads perfused with autologous blood. Domest. Anim. Endocrinol. 14, 149-160 (1997).
11. Huang Y.P., Guo D.C., Peter R.E.: Isolation and characterization of a gonadotropin-releasing hormone binding protein in goldfish serum, Gen. Comp. Endocrinol. 84, 58-66 (1991).
12. Fasano S., de Leeuw, R., Pierantoni R., ChieffiG., van Oordt P.G.: Characterization of gonadotropin-releasing hormone (GnRH) binding sites in the pituitary and testis of the frog Rana esculenta. Biochem. Biophys. Res. Commun. 168, 923-932 (1990).
13. Barda Y., Cohen N., Lev V., Ben-Aroya N., Koch Y., Mishani E., Fridkin M., Gilon C.: Backbone metal cyclization: novel 99 Tc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nucl. Med. Biol. 31, 921-33 (2004).
14. Jalilian A.R., Shanehsazzadeh S., Kamali-dehghan M., Akhlaghi M.: Development of [111In]-DTPA-Buserelin for GnRH receptor studies. Radiochimica Acta, 98, 113-119 (2010).
15. Guo H., Lu J., Hathaway H., Royce M.E., Prossnitz E.R., Miao Y.: Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-Targeting peptides. Bioconjug Chem. 22, 682-689 (2011).
16. Sudbrock F., Fischer T., Zimmermanns B., Guliyev M., Dietlein M., Drzezga A., Schomäcker K.: Characterization of SnO 2-based 68Ge/68Ga generators and 68Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-Term constancy. EJNMMI Res. 4, 36 (2014).
17. Velikyan I.: Prospective of 68Ga-radiopharmaceutical development, Theranostics 4, 47-80 (2014).
18. Jalilian A.R., Rowshanfarzad P., Sabet M., Novinrooz A., Raisali G.: Preparation of [66Ga]bleomycin complex as a possible PET radiopharmaceutical. J. Radioanal. Nucl. Chem. 264, 617-624 (2005).
19. Breeman W.A., de Jong M., de Blois E., Bernard B.F., Konijnenberg M., Krenning E.P.: Radiolabeling DOTA-peptides with 68Ga. Eur. J. Nucl. Med. Mol. Imaging 32, 478-85 (2005).
20. http://www.drugs.com/dosage/triptorelin.html.
21. Aghanejad A., Jalilian A.R., Ardaneh Kh., Bolourinovin F., Yousefnia H., Bahrami Samani A.: Preparation and quality control of 68Ga-citrate for PET applications. Asia Oceania J. Nucl. Med. Biol. 3, 99-106 (2015).
22. Kamada M.: Distribution of 67Ga-citrate in tumor tissues and various organs. Radioisotopes (Tokyo) 27, 390-396 (1978).
23. http://www.pfizer.com/files/products/uspi-Trelstar-la.pdf.
24. Bull P., Morales P., Huyser C., Socías T., Castellón E.A.: Expression of GnRH receptor in mouse and rat testicular germ cells. Mol. Hum. Reprod. 6, 582-586 (2000).
25. Sand E., Bergvall M., Ekblad E., DAmato M., Ohlsson B.: Expression and distribution of GnRH, LH and FSH and their receptors in gastrointestinal tract of man and rat. Regul. Pept., 187, 24-28 (2013).